Cargando…

The United States Food and Drug Administration and Prescription Drug Promotion

The impact of prescription drug promotion on health-care professionals (HCPs) is significant. Pharmaceutical industry spending on promotion to HCPs greatly outpaces spending on direct-to-consumer promotion. According to Syneos Health™ PromotionalAnswers, in 2017, the pharmaceutical industry spent mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalola, Ankur S., Dean, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MediaSphere Medical 2019
Materias:	Research Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252651/ https://www.ncbi.nlm.nih.gov/pubmed/32477722 http://dx.doi.org/10.19102/icrm.2019.100305

Ejemplares similares

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration
por: Sullivan, Helen W., et al.
Publicado: (2016)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?
por: Schatman, Michael E, et al.
Publicado: (2020)

A Summary of the United States Food and Drug Administrations’ Food Safety Program for Imported Seafood; One Country’s Approach
por: Koonse, Brett
Publicado: (2016)

Antimicrobial Drug Prescription and Neisseria gonorrhoeae Susceptibility, United States, 2005–2013
por: Kirkcaldy, Robert D., et al.
Publicado: (2017)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Association between unemployment rates and prescription drug utilization in the United States, 2007–2010
por: Kozman, Daniel, et al.
Publicado: (2012)

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review
por: Mukherjee, Sanjana
Publicado: (2023)

Characteristics of State Legislation Addressing Prescription Drug Price Increases in the United States, 2020
por: Shahriar, Arman A., et al.
Publicado: (2021)

Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000
por: McCaig, Linda F., et al.
Publicado: (2003)

Trends in Prices of Popular Brand-Name Prescription Drugs in the United States
por: Wineinger, Nathan E., et al.
Publicado: (2019)

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
por: Wu, Ziyang, et al.
Publicado: (2022)

United States Food and Drug Administration’s authorization of reduced exposure claims for IQOS(®): implications for regulation in Latin America
por: Eckford, Robert, et al.
Publicado: (2022)

Artificial Intelligence and Machine Learning in the Diagnosis and Management of Stroke: A Narrative Review of United States Food and Drug Administration-Approved Technologies
por: Chandrabhatla, Anirudha S., et al.
Publicado: (2023)

Dietary Exposure to United States Food and Drug Administration-Approved Synthetic Food Colors in Children, Pregnant Women, and Women of Childbearing Age Living in the United States
por: Bradman, Asa, et al.
Publicado: (2022)

The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)

Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States
por: de Dios, Constanza, et al.
Publicado: (2021)

Food and Drug Administration guidances on biosimilars: an update for the gastroenterologist
por: Epstein, Michael
Publicado: (2018)

Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
por: Nacif, Marcelo S, et al.
Publicado: (2012)

Concurrent Use of Opioids and Benzodiazepines: Evaluation of Prescription Drug Monitoring by a United States Laboratory
por: McClure, Fred Leland, et al.
Publicado: (2017)

Recent trends in prescription drug misuse in the United States by age, race/ethnicity, and sex
por: Schepis, Ty S., et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

United States Food and Drug Administration’s 510(k) Pathway: Drawing Implications from the Approvals of Brachytherapy Devices
por: Wang, Sophie, et al.
Publicado: (2019)

Adverse events related to total ankle replacement devices: an analysis of reports to the United States Food and Drug Administration
por: Mahmoud, Karim, et al.
Publicado: (2021)

Racial and Ethnic Disparities and Prevalence in Prescription Drug Misuse, Illicit Drug Use, and Combination of Both Behaviors in the United States
por: Lee, Yen-Han, et al.
Publicado: (2023)

State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995–2017: A difference-in-differences analysis
por: Earlywine, Joel J., et al.
Publicado: (2020)

Promotion of Prescription Drugs to Consumers and Providers, 2001–2010
por: Kornfield, Rachel, et al.
Publicado: (2013)

The Association between Non-Medical Prescription Drug Use and Suicidal Behavior among United States Adolescents
por: Divin, Amanda L., et al.
Publicado: (2014)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
por: Sullivan, Emma, et al.
Publicado: (2020)

An in silico–in vitro pipeline for drug cardiotoxicity screening identifies ionic pro‐arrhythmia mechanisms
por: Clark, Alexander P., et al.
Publicado: (2022)

Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
por: Chua, Kao-Ping, et al.
Publicado: (2021)

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
por: Hoffman, Keith B., et al.
Publicado: (2014)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
por: Cross, Raymond K., et al.
Publicado: (2019)

Drug reimportation practices in the United States
por: Bhosle, Monali J, et al.
Publicado: (2007)

Direct-to-consumer advertising and expenditures on prescription drugs: a comparison of experiences in the United States and Canada
por: Morgan, Steven G
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_g9qhje20pfncm2la5lvdce7td7